domperidone sold brand name motilium among others dopamine antagonist medication used treat nausea vomiting certain gastrointestinal problems like gastroparesis delayed gastric emptying raises level prolactin human body used induce promote breast milk may taken mouth side effects domperidone include headache dry mouth abdominal cramps diarrhea elevated prolactin secondary increased prolactin levels breast changes milk outflow menstrual irregularities hypogonadism domperidone may also cause qt prolongation rarely associated serious cardiac complications sudden cardiac however risks small occur high domperidone acts peripherally selective antagonist dopamine due low entry brain side effects domperidone different dopamine receptor antagonists like metoclopramide produces little way central nervous system adverse however domperidone nonetheless increase prolactin levels pituitary gland outside domperidone discovered introduced medical use developed janssen domperidone available overthecounter many countries instance europe elsewhere throughout approved use united however available united states people severe treatmentrefractory gastrointestinal motility problems expanded access individualpatient investigational new drug analogue domperidone called deudomperidone also currently development potential use united states evidence domperidone antiemetic recommended canadian headache society treatment nausea associated acute gastroparesis medical condition characterised delayed emptying stomach mechanical gastric outlet obstruction cause commonly idiopathic diabetic complication result abdominal surgery condition causes nausea vomiting fullness eating early satiety feeling full meal finished abdominal pain bloating domperidone used increase transit food stomach increasing gastrointestinal peristalsis hence treat may useful idiopathic diabetic however increased rate gastric emptying induced drugs like domperidone always correlate well relief hormone prolactin stimulates lactation dopamine released hypothalamus stops release prolactin pituitary gland domperidone acting antidopaminergic agent results increased prolactin secretion thus promotes lactation galactogogue domperidone moderately increases volume expressed breast milk mothers preterm babies breast milk expression inadequate appears safe shortterm use united states domperidone approved study called empower trial designed assess effectiveness safety domperidone assisting mothers preterm babies supply breast milk study randomized mothers preterm babies receive either domperidone mg orally three times daily days group placebo mg orally three times daily days followed domperidone mg orally three times daily days group b mean milk volumes beginning intervention similar groups first days mothers receiving domperidone group achieved increase milk volume mothers receiving placebo group b achieved increase milk induce lactation domperidone used dosage mg times per day effects may seen within hours may seen maximum effect occurs weeks treatment treatment period generally lasts review shows studies support prophylactic use galactagogue medications including domperidone stage parkinsons disease degenerative neurological condition decrease dopamine brain leads rigidity stiffness movement tremor symptoms signs poor gastrointestinal function nausea vomiting major problem people parkinsons disease medications used treat parkinsons disease given mouth medications levodopa cause nausea side effect furthermore antinausea drugs metoclopramide cross barrier may worsen extrapyramidal symptoms parkinsons disease domperidone used relieve nausea gastrointestinal symptoms parkinsons disease blocks peripheral receptors minimally crosses barrier normal doses effect extrapyramidal symptoms domperidone may used functional dyspepsia adults also found effective treatment reflux however specialists consider risks prohibitory treatment infantile domperidone available use oral administration form tablets orally disintegrating tablets suspension rectal administration form oral tablets available strength domperidone studied use intramuscular injection intravenous formulation previously available medication available forms oral rectal domperidone contraindicated qtprolonging drugs like side effects associated domperidone include dry mouth abdominal cramps diarrhea nausea rash itching hives hyperprolactinemia symptoms may include breast enlargement galactorrhea breast paintenderness gynecomastia hypogonadism menstrual due blockade receptors central nervous system receptor antagonists like metoclopramide antipsychotics also produce variety additional side effects including drowsiness akathisia restlessness insomnia lassitude fatigue extrapyramidal symptoms dystonia parkinsonian symptoms tardive dyskinesia however case domperidone unlike receptor antagonists minimally crosses barrier reason rarely associated side however domperidone theoretically might able produce blockade central receptors higher doses turn producing side effects similar centrally permeable receptor antagonists like due receptor blockade domperidone causes hyperprolactinemia suppress secretion gonadotropinreleasing hormone gnrh hypothalamus turn suppressing secretion folliclestimulating hormone fsh luteinizing hormone lh resulting hypogonadism low levels sex hormones estradiol accordingly females reported experience mammoplasia breast enlargement mastodynia breast paintenderness galactorrhea inappropriate excessive milk productionsecretion amenorrhea cessation menstrual cycles domperidone males may experience low libido erectile dysfunction impaired spermatogenesis well galactorrhea receptor antagonists like antipsychotics domperidone may also increase risk prolactinomas research needed confirm domperidone use associated increased risk sudden cardiac death likely prolonging effect cardiac qt interval ventricular cause thought blockade herg voltagegated potassium risks dosedependent appear greatest highvery high doses via intravenous administration elderly well drugs interact domperidone increase circulating concentrations namely conflicting reports exist neonates infants qt prolongation controversial uk drug regulatory authorities mhra issued following restriction domperidone due increased risk adverse cardiac domperidone motilium associated small increased risk serious cardiac side effects use restricted relief nausea vomiting dosage duration use reduced longer used treatment bloating heartburn domperidone contraindicated underlying cardiac conditions risk factors patients conditions patients receiving longterm treatment domperidone reassessed routine appointment light new advice however australian review concluded based results two tqt regulatory agency gold standard assessment qt prolongation domperidone appear strongly associated qt prolongation oral doses mg qid healthy volunteers limited case reports supporting association cardiac dysfunction frequently cited casecontrol studies significant flaws remains illdefined risk higher systemic concentrations especially patients higher baseline risk qt prolongation review support view domperidone presents intolerable risk britain legal case involved death two children mother whose three children hypernatraemia charged poisoning children salt one children born weeks gestation respiratory complications fundoplication gastroesophageal reflux failure thrive prescribed domperidone advocate mother suggested child may neuroleptic malignant syndrome side effect domperidone due drug crossing childs immature healthy volunteers inhibitor ketoconazole increased cmax auc concentrations domperidone accompanied qt interval prolongation milliseconds domperidone mg four times daily ketoconazole mg twice daily administered whereas domperidone dosage assessed produced domperidone ketoconazole inhibitors potentially dangerous domperidone peripherally selective dopamine receptor clinically significant interaction receptor unlike medication provides relief nausea blocking receptors chemoreceptor trigger zone gastrointestinal symptoms blocking receptors blocks receptors lactotrophs anterior pituitary gland increasing release prolactin turn increases domperidone may useful patients cause harm others way genetics person polymorphisms drug transporter gene encodes pglycoprotein voltagegated potassium channel gene receptor single mg oral dose domperidone found increase mean serum prolactin levels measured minutes postadministration nonlactating women ngml ngml similar increase prolactin levels produced single mg oral dose metoclopramide ngml ngml two weeks repeated administration mgday cases increase prolactin levels produced domperidone reduced ngml baseline increase prolactin levels produced metoclopramide conversely heightened ngml indicates acute continuous administration domperidone metoclopramide effective increasing prolactin levels different effects secretion prolactin repeated mechanism difference increase prolactin levels observed two drugs much greater women appears due higher estrogen levels women estrogen stimulates prolactin secretion pituitary comparison normal prolactin levels women less ngml prolactin levels peak ngml parturition pregnant women lactating women prolactin levels found ngml days postpartum ngml days absolute bioavailability domperidone low approximately due extensive firstpass metabolism intestines conversely bioavailability high via intramuscular injection onset action domperidone taken orally peak levels domperidone following oral dose occur domperidone exposure increases proportionally doses mg dose accumulation levels domperidone frequent repeated oral administration domperidone four times per day every hours oral bioavailability domperidone somewhat increased time peak slightly increased taken food bioavailability decreased prior concomitant administration cimetidine sodium plasma protein binding domperidone tissue distribution domperidone based animal studies wide concentrations low drug substrate pglycoprotein transporter animal studies suggest reason low central nervous system penetration small amounts domperidone cross placenta domperidone extensively metabolized liver intestines oral occurs via hydroxylation domperidone almost exclusively metabolized though minor contributions major enzyme involved ndealkylation domperidone involved aromatic metabolites domperidone inactive receptor overall peak levels domperidone increased moderate hepatic impairment domperidone eliminated urine proportion domperidone excreted unchanged small feces elimination halflife domperidone hours healthy however elimination halflife domperidone prolonged hours people several renal domperidone benzimidazole derivative structurally related butyrophenone neuroleptics like domperidone synthesized janssen pharmaceutica following research antipsychotic janssen pharmacologists discovered antipsychotic drugs significant effect dopamine receptors central chemoreceptor trigger zone regulated vomiting started searching dopamine antagonist would pass barrier thereby free extrapyramidal side effects associated drugs led discovery domperidone strong antiemetic minimal central domperidone patented united states patent filed needed domperidone first marketed brand name motilium switzerland west domperidone subsequently introduced forms orally disintegrating tablets based zydis technology janssen pharmaceutical brought domperidone united states federal drug administration fda several times including approved april coordination group mutual recognition decentralised procedures human cmdh published official pressrelease suggesting restrict use domperidonecontaining medicines also approved earlier published suggestions pharmacovigilance risk assessment committee prac use domperidone treating nausea vomiting reduce maximum daily dosage domperidone generic name drug inntooltip international nonproprietary name usantooltip united states adopted name bantooltip british approved name jantooltip japanese accepted reported domperidone available countries including uses indications domperidone vary nations italy used treatment gastroesophageal reflux disease canada drug indicated upper gastrointestinal motility disorders prevent gastrointestinal symptoms associated use dopamine agonist antiparkinsonian united kingdom domperidone indicated treatment nausea vomiting treatment duration usually limited week united states domperidone currently legally marketed human drug approved sale united states june fda issued public warning distributing domperidonecontaining products available overthecounter treat gastroesophageal reflux functional dyspepsia many countries ireland netherlands italy south africa mexico india chile domperidone generally approved use united states exception use people treatmentrefractory gastrointestinal symptoms fda investigational new drug domperidone studied potential hormonal contraceptive prevent pregnancy httpsenwikipediaorgwikidomperidone